Mutational landscape of TP53 and CDH1 in gastric cancer  

作　　者：Hong-Qiao Cai Li-Yue Zhang Li-Ming Fu Bin Xu Yan Jiao 

机构地区：[1]Department of Hepatobiliary and Pancreatic Surgery,General Surgery Center,The First Hospital of Jilin University,Changchun 130021,Jilin Province,China [2]Department of Critical Care Medicine,The First Hospital of Jilin University,Changchun 130021,Jilin Province,China [3]Department of Traditional Chinese Medicine,The First Hospital of Jilin University,Changchun 130021,Jilin Province,China

出　　处：《World Journal of Gastrointestinal Surgery》2024年第2期276-283,共8页世界胃肠外科杂志（英文版）（电子版）

基　　金：Supported by the Youth Development Fund Task Book of the First Hospital of Jilin University,No.JDYY13202210.

摘　　要：In this editorial we comment on an article published in a recent issue of the World J Gastrointest Surg.A common gene mutation in gastric cancer(GC)is the TP53 mutation.As a tumor suppressor gene,TP53 is implicated in more than half of all tumor occurrences.TP53 gene mutations in GC tissue may be related with clinical pathological aspects.The TP53 mutation arose late in the progression of GC and aided in the final switch to malignancy.CDH1 encodes E-cadherin,which is involved in cell-to-cell adhesion,epithelial structure maintenance,cell polarity,differentiation,and intracellular signaling pathway modulation.CDH1 mutations and functional loss can result in diffuse GC,and CDH1 mutations can serve as independent prognostic indicators for poor prognosis.GC patients can benefit from genetic counseling and testing for CDH1 mutations.Demethylation therapy may assist to postpone the onset and progression of GC.The investigation of TP53 and CDH1 gene mutations in GC allows for the investigation of the relationship between these two gene mutations,as well as providing some basis for evaluating the prognosis of GC patients.

关 键 词：TP53 CDH1 Gastric cancer Gene mutation METHYLATION 

分 类 号：R735.2[医药卫生—肿瘤]